Inflammation News and Research

RSS

Once-a-week arthritis pill significantly reduces the risk of heart attacks

A once-a-week pill to treat rheumatoid arthritis significantly reduces the risk of heart attack and stroke for people with the painful joint condition.

10 Mar 2008

New potential drug target for atherosclerosis

A nuclear receptor protein, known for controlling the ability of cells to burn fat, also exerts powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice prone to developing the harmful plaques, according to new research by scientists at the Salk Institute for Biological Studies and the Harvard School of Public Health.

6 Mar 2008

New research aims to eliminate Streptococcus infections

Professor Howard Jenkinson in the Department of Oral & Dental Science (Dental School) at the University of Bristol has been awarded a grant of £285,000 from The Wellcome Trust to research ways to combat diseases caused by Streptococcus bacteria.

5 Mar 2008

Watery pools in bone marrow key to psoriatic arthritic damage

Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases.

4 Mar 2008

New way to develop tumor vaccines

Researchers at the University of Southern California (USC) have uncovered a new way to develop more effective tumor vaccines by turning off the suppression function of regulatory T cells.

3 Mar 2008

FzioMed's Oxiplex gel for spine surgery approved in Canada

FzioMed, Inc. (www.fziomed.com) has announced that Health Canada has approved the company's Oxiplex gel for use in lumbar spine surgery.

1 Mar 2008

Effect of tumor necrosis factor a inhibitors on heart failure risk in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is characterized by persistent inflammation of the synovial membrane and progressive joint destruction.

28 Feb 2008

Discovery of potential drug targets for sepsis

"We have identified a key connection of signaling pathways in the cascade of events leading to sepsis. This defines a crucial point where the immune system spirals out of control to cause severe sepsis and where there is an opportunity for therapeutic intervention," says Scripps Research Professor Wolfram Ruf, who led the research with his postdoctoral fellow Frank Niessen.

28 Feb 2008

Overweight Hispanic children shown to have vascular inflammation

Overweight Hispanic children with normal blood glucose (sugar) levels showed elevated markers for blood vessel inflammation that may predispose them to developing both type 2 diabetes and cardiovascular disease, says a new study led by researchers from the Joslin Diabetes Center.

28 Feb 2008

FDA approves Arcalyst for treatment of rare inflammatory syndromes

The U.S. Food and Drug Administration has approved a drug to help ease the suffering faced by those with certain chronic inflammatory diseases.

28 Feb 2008

Risks of CVD for COX-2 inhibitors lower than previously reported

In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).

27 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008